Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease.
Inc. ("bluebird bio") today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and ...